CME Presentations

Hemophilia A



  • Kelly Tickle, MSN, APN, PCNS-BC, PPCNP-BC

    Kelly Tickle, MSN, APN, PCNS-BC, PPCNP-BC

    Kelly Tickle, MSN, APN, PCNS-BC, PPCNP-BC

    Kelly Tickle, MSN, APN, PCNS-BC, PPCNP-BC, works at Children’s Healthcare of Atlanta in the Hemophilia Treatment Center as the hematology nurse practitioner. Her clinical and research interest is in investigating adolescents and women with bleeding disorders who have heavy menses. Kelly was the recipient of the National Hemophilia Foundation Nursing Research Grant to study quality of life for females with bleeding disorders and heavy menstruation. She graduated with her Master of Science in nursing from Union University with dual concentrations of pediatric nurse practitioner and pediatric clinical nurse specialist. After receiving her graduate degree, Kelly practiced as a clinical nurse specialist for the brain tumor program at St. Jude Children’s Research Hospital.
  • Steven Pipe, MD

    Steven Pipe, MD

    Steven Pipe, MD

    Steven W. Pipe, MD, is professor and the Laurence A. Boxer Research Professor of pediatrics and professor of pathology at the University of Michigan in Ann Arbor. He is medical director of the Pediatric Hemophilia and Coagulation Disorders Program and the Special Coagulation Laboratory. Dr Pipe’s clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies, and he directs a lab investigating the molecular mechanisms of hemophilia A. He was the 2015 recipient of the Leadership in Research Award from the National Hemophilia Foundation. Dr Pipe has served as chair of the board of directors for the American Thrombosis and Hemostasis Network and is currently chair of the Medical and Scientific Advisory Council to the National Hemophilia Foundation.
  • Stacy Croteau, MD, MMS

    Stacy Croteau, MD, MMS

    Stacy Croteau, MD, MMS

    Stacy E. Croteau, MD, MMS, is a pediatric hematologist and clinical investigator at Boston Children’s Hospital and assistant professor of Pediatrics at Harvard Medical School. She is the head of the Hemophilia/VWD program Boston Children’s Hospital and medical director for the Boston Hemophilia Center serving Boston Children’s Hospital and Brigham and Women’s Hospital. Dr Croteau is the principle investigator for several industry-sponsored and investigator-initiated clinical trials on hemophilia and other bleeding and clotting disorders. She has published numerous original research and review articles in peer-reviewed journals and presents nationally and internationally on a broad spectrum of bleeding disorder topics for medical professionals as well as the bleeding disorders community.

CME Information

Optimizing Prophylaxis Strategies of Hemophilia A with or without Inhibitors: For Whom, When, and How Long?

Global LogoPQH Logo


After completing this activity, the participant should be better able to:

  • Identify the numerous clinical factors when determining a therapeutic plan for your patient with hemophilia A
  • Evaluate the mechanisms, safety, and efficacy of currently available products for bleeding prophylaxis in patients with severe hemophilia A
  • Summarize best practices when managing patients with hemophilia A with inhibitors
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by an educational grant from Genentech, a member of the Roche Group.


June 18, 2020 – June 18, 2021


The educational design of this activity addresses the needs of hematologists, pediatric hematologists, hematologist-oncologists, pediatricians, pharmacists, hemophilia pharmacists, hemophilia nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia.


Hemophilia A (factor VIII [factor 8] deficiency) is an X-linked inherited coagulation factor deficiency. The management of hemophilia A has improved significantly in recent years with the availability of factor replacement agents, such as with extended half-life replacement agents and non-factor replacement therapy. Unfortunately, the optimal management remains complex and poses significant challenges for clinicians who care for patients with hemophilia. This is highlighted in outcomes results from recent educational activities.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity was released on June 18, 2020 and is valid for 12 months. Requests for credit must be made no later than June 18, 2021.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Stacy E. Croteau, MD, MMS
Director Hemophilia/VWD program, Boston Children's Hospital
Medical Director, Boston Hemophilia Center
Assistant Professor of Pediatrics, Harvard Medical School
Consultant/Independent Contractor:
Genentech, Sigilon, Tremeau Pharmaceuticals
Grant/Research Support to institution:
Boehringer Ingelheim, Novo Nordisk, Pfizer, Spark Therapeutics
Honoraria: Bayer, Hemophilia Federation of America (HFA), National Hemophilia Foundation (NHF), Pfizer
Advisory Board: ATHN, Hemophilia Alliance, THSNA
Steven Pipe, MD
Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Consultant/Independent Contractor: Apcintex, Bayer, Biomarin, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda, Spark Therapeutics, uniQure (NOTE: No individual relationship exceeds $20000).
Hematology Pediatric Nurse Practitioner for the Comprehensive Bleeding Disorder Center
Children’s Healthcare of Atlanta
Grant/Research Support: National Hemophilia Foundation Nursing Excellence Fellowship Grant Program

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Ashley Marostica, RN, MSN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Alissa Yost Nothing to disclose
Bridget Griffin Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.